Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 39

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Acute lymphocytic leukaemia+4

Recruiting

Study of Dasatinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with MAPK/SRC Pathway Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Dasatinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Acute myeloid leukaemia

Recruiting

Study comparing venetoclax with intensive chemotherapy (daunorubicin, cytarabine, gemtuzumab ozogamicin) in patients with favorable risk acute myeloid leukemia

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:The University Of Birmingham

Myeloproliferative neoplasm

Recruiting

Study on the Effects of Atorvastatin for Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Region Sjaelland

Plasma cell myeloma

Recruiting

Study on Daratumumab, Carfilzomib, Pomalidomide, and Dexamethasone for Patients with Multiple Myeloma and Acute Kidney Failure

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Medizinische Universitaet Innsbruck

Plasma cell myeloma

Not yet recruiting

Dapagliflozin for Primary Cardioprotection in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation – A Randomized Phase 2 Study

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Instytut Hematologii I Transfuzjologii

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Paroxysmal nocturnal haemoglobinuria

Not yet recruiting

Study of VSA012 Sodium in Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Complement Inhibitor‑Naïve or Have Persistent Anemia on C5 Inhibitor Therapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Chronic lymphocytic leukaemia

Not yet recruiting

Safety and Efficacy of MK-1045 with Tocilizumab in Patients with CLL/SLL

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma refractory

Not yet recruiting

Study of elranatamab, mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Fundacion PETHEMA

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of Ibrutinib Plus Ritonavir in Adults with Chronic Lymphocytic Leukemia, Lymphoplasmacytic Lymphoma, and Mantle Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Paroxysmal nocturnal haemoglobinuria+1

Not yet recruiting

Long‑Term Safety and Tolerability of Oral Iptacopan in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria or IgA Nephropathy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.